CL-150390
Received: April 24, 2015 | Accepted: May 20, 2015 | Web Released: May 30, 2015
Synthesis of Sitagliptin Phosphate by a NaBH4/ZnCl2-catalyzed Diastereoselective Reduction
Xianhua Pan,# Kun Wang,# Wansheng Yu, Ruimin Zhang, Lu Xu, and Feng Liu*
School of Perfume and Aroma Technology, Shanghai Institute of Technology, 100 Haiquan Rd, Shanghai, 201418, P. R. China
(E-mail: liufeng@sit.edu.cn)
F
F
F
F
Ph
CONH2
NH
A practical asymmetric synthesis of sitagliptin phosphate,
from 1-{3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo-[4,3-
a]pyrazin-7(8H)-yl}-4-(2,4,5-trifluorophenyl)butane-1,3-dione,
in overall 65.3% yield has been reported. The target compound
was synthesized via eneamination, diastereoselective reduction,
amine-deprotection, and phosphatization. The key diastereose-
lective reduction was performed with NaBH4 and ZnCl2, and it
gave the product with almost quantitative yield and 68.5% d.e.
value after simple work-up and recrystallization with IPA/PE;
a high enantiopurity (d.e.% = 99.3%) can also be obtained in
57.1% yield.
Ph
CONH2
NH2
NaBH4/ZnCl2
THF, quantitative
F
F
O
O
O
AcOH
N
N
d.e. = 68.5 % and
can be purified to
>99% after
N
N
N
N
i-PrOH, 91.3 %
N
N
CF3
simple recryst.
3
CF3
2
F
F
F
Ph
CONH2
NH
H3PO4
NH2
1) 5% Pd(OH)2/C
F
F
O
O
HCOOH, H2O,MeOH/THF
N
N
N
N
2) H3PO4, i-PrOH/H2O
N
N
F
N
N
89.3 % for 2 steps
CF3
CF3
sitagliptin phosphate
4
1
Scheme 1. Synthesis of sitagliptin phosphate.
Diabetes, a fast growing global epidemic that affects
millions of people, is caused by multiple reasons and can be
characterized by divided levels of plasma glucose in the rapid
or post glucose-challenge state. Two types of diabetes can be
generally recognized: Type 1 diabetes mellitus (T1DM), wherein
patients generate none or trace insulin, which cut down glucose,
and Type 2 diabetes mellitus (T2DM), in which patients can
generate insulin normally, but this insulin has a poor effect in
regulating glucose utilization. In a recent study, inhibitors of
dipeptidyl peptidase IV (DPP-IV) could generate fresh ther-
apeutic agents for T2DM by stimulating GLP-1 (glucagon-like
peptide-1) and GIP (glucose-dependent insulinotropic peptide)
levels, as well as boosting glycemic control for diabetics.
Sitagliptin phosphate 1 (Figure 1), the representative drug
for the treatment of T2DM, was approved by USFDA in 2006,
which received almost 4 billion saleroom in 2013, being worthy
of the name “heavy bomb drug.” Due to the unique structure and
good market performance, a large number of synthetic routes of
sitagliptin phosphate have been developed in the past decade.
Kim et al.1 reported an ingenious way to obtain the target
compound at 2005, but this needs quite strict reaction conditions
such as a low temperature (¹78 °C) and a dangerous reagent
(CH2N2). A method to obtain the key intermediate (β-amino acid
derivative) of sitagliptin phosphate has been developed by Xiao
et al.2 at 2004, which was carried out by metal-catalyzed
asymmetric hydrogenation; however, even if the chiral amido-
gen were created inventively, the cost of using the expensive
([Rh(cod)2]OTf) limited this process to the laboratory and small
scale, so did (S-BINAP),3 RuCl2,3 [(R)-(R)-t-Bu JOSIPHOS],4
(R-DM-SEGPHOS),5 and PtO2.6,7 Therefore, applying a cheap,
safe, and large-scale method to obtain sitagliptin phosphate or its
intermediates has become the scientists’ unremitting goal.
In 2013, a novel method that achieved the intermediate of
sitagliptin phosphate in a certain chiral purity (d.e.% = 50%)
by using a cheap reductant (NaBH4 and aliphatic acid) was
developed by Lin and colleagues,8 which revealed that a cheap
and simple reductive system can also catalyze the substrate
controlled diastereoselective reduction to a certain extent.
As a part of our interests in developing practical and simple
approaches for the synthesis of sitagliptin phosphate and other
active pharmaceutical ingredients (API) as well as the inter-
mediates,9 we report here an efficient approach to the synthesis
of sitagliptin phosphate 1 (Scheme 1) by a NaBH4/Lewis acid-
catalyzed diastereoselective reduction reaction10 and the follow-
ing work-up.11-14
The synthesis began from compound 2,2 after treating it
with (S)-phenylglycine amide in the presence of AcOH in IPA,
compound 3 was obtained in good yield (91%) and high HPLC
purity (99%).
Then, with the key intermediate, enamine compound 3 in
hand, the Lewis acid-catalyzed diastereoselective reduction was
examined carefully. As indicated in Table 1, it could be easily
found that NaBH4-ZnCl2 has better catalytic ability among the
four different NaBH4-Lewis acids (Entries 1-4) at 0 °C in THF,
resulting in 59.4% yield and 51.7% diastereomeric excess.
Then, the reaction mixture was frozen to ¹60 °C to enhance the
chiral selectivity, and a better yield and enantioselectivity were
obtained (Entry 5). We were happy to find that on decreasing
the loading of ZnCl2 to 0.7 equiv (Entry 6), the diastereomeric
pair of 4 could be quantitatively obtained with a satisfactory
diastereoselectivity (d.e.% = 68.5%). However, unfortunately,
further decreasing ZnCl2 to 0.35 equiv gave us a worse result,
and both the yield and d.e. value were reduced (Entry 7). We
then tried to adjust the reaction temperature to a moderate level
in order to reduce the energy consumption, but with the increase
in the temperature, the reaction yield decreased, and the
stereoselectivity was less than satisfactory (Entries 8-10).
CF3
N
N
N
F
F
N
(R)
O
NH2
F
H3PO4
Sitagliptin phosphate
1
Figure 1. Structure of sitagliptin phosphate.
© 2015 The Chemical Society of Japan